IM Cannabis (IMCC) Cash from Financing Activities (2020 - 2025)
IM Cannabis' (IMCC) quarterly Cash from Financing Activities came in at -$1.5 million in Q4 2025, down 155.26% year-on-year from $2.8 million in Q4 2024, and down 134.36% quarter-over-quarter from $4.4 million in Q3 2025.
IM Cannabis (IMCC) Cash from Financing Activities (2020 - 2025) Analysis & Trends
IM Cannabis' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at -$1.5 million for Q4 2025.
- On a quarterly basis, Cash from Financing Activities fell 155.26% year-over-year to -$1.5 million in Q4 2025; TTM through Dec 2025 was $938116.2, a 65.6% decrease from a year earlier, with the FY2025 full-year figure at $821780.9, down 70.59% from the prior year.
- Cash from Financing Activities slipped to -$1.5 million in Q4 2025 per IMCC's latest filing, from $4.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $35.0 million in Q2 2021 and bottomed at -$3.2 million in Q3 2022.
- The 5-year median for Cash from Financing Activities is $1.2 million (2022), against an average of $2.7 million.
- Across the five-year window, Cash from Financing Activities tumbled 268.24% in 2022 and surged 10232.79% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $2.2 million in 2021, then sank by 38.36% to $1.4 million in 2022, then slumped by 101.99% to -$27177.8 in 2023, then jumped by 10232.79% to $2.8 million in 2024, then plunged by 155.26% to -$1.5 million in 2025.
- Per Business Quant, the three latest IMCC Cash from Financing Activities figures stand at -$1.5 million (Q4 2025), $4.4 million (Q3 2025), and $32477.1 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | IM Cannabis | 591,792.44 | -193,562.09 | 1.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.52 Mn |
| Dec 31, 2025 | -1.52 Mn |
| Sep 30, 2025 | 4.43 Mn |
| Sep 30, 2025 | 4.43 Mn |
| Jun 30, 2025 | 32,477.06 |
| Jun 30, 2025 | 32,477.06 |
| Mar 31, 2025 | -2.00 Mn |
| Mar 31, 2025 | -2.00 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | -487,480.52 |
| Sep 30, 2024 | -487,480.52 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | -632,280.45 |
| Mar 31, 2024 | -632,280.45 |
| Dec 31, 2023 | -27,177.81 |
| Dec 31, 2023 | -27,177.81 |
| Sep 30, 2023 | -912,272.96 |
| Sep 30, 2023 | -912,272.96 |